• 1
    Dawood FS, Iuliano AD, Reed C et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12:687695.
  • 2
    WHO. Summary of WHO technical consultation: H1N1pdm mortality estimates, 2011, 25–26 October 2011. Available at (Accessed 1 June 2012).
  • 3
    WHO. Influenza-like illness in the United States and Mexico, 2009. Available at (Accessed 31 December 2012).
  • 4
    WHO. World Health Organization, situation updates – pandemic (H1N1), 2009. Available at (Accessed 31 December 2012).
  • 5
    WHO. Human infection with pandemic (H1N1), 2009 virus: updated interim WHO guidance on global surveillance, 2009. Available at World Health Organization. 10 July 2009.
  • 6
    WHO. H1N1 in post-pandemic period, 2010. Director-General's opening statement at virtual press conference, 10 August 2010. Available at
  • 7
    WHO. World Health Organization. Situation update pandemic (H1N1), 2009 – update 112, 2010. Available at: (Accessed 31 December 2012).
  • 8
    Wu JT, Ho A, Ma ES et al. Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. PLoS Med 2011; 8:e1001103. Epub 2011 Oct 4.
  • 9
    Wu JT, Ma ES, Lee CK et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 2010; 51:11841191.
  • 10
    Van Kerkhove MD, Asikainen T, Becker NG et al. Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLoS Med 2010; 7:e1000275.
  • 11
    Lipsitch M, Finelli L, Heffernan RT, Leung GM, Redd SC, 2009 H1N1 Surveillance Group. Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1. Biosecur Bioterror 2011; 9:89115.
  • 12
    WHO. Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec 2010; 24:229236.
  • 13
    CDC. 2009 Pandemic influenza A (H1N1) virus infections – Chicago, Illinois, April–July 2009. MMWR Morb Mortal Wkly Rep 2009; 58:913918.
  • 14
    Cauchemez S, Donnelly CA, Reed C et al. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med 2009; 361:26192627.
  • 15
    Fraser C, Donnelly CA, Cauchemez S et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324:15571561.
  • 16
    Laurie KL, Huston P, Riley S et al. Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting. Influenza Other Respir Viruses 2012; doi: 10.1111/j.1750-2659.2012.0370a.x.
  • 17
    Kelly H, Peck HA, Laurie KL, Wu P, Nishiura H, Cowling BJ. The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination. PLoS ONE 2011; 6:e21828.
  • 18
    WHO. FLUNET the reporting tool of the global influenza surveillance network, 2010. Available at (Accessed 31 December 2012).
  • 19
    Van Kerkhove MD, Vandemaele KAH, Shinde V et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8:e1001053.
  • 20
    United Nations. United Nations Population Division. World population prospects: the 2010 revision, 2010. Available at (Accessed 24 January 2012).
  • 21
    The World Bank. Population density (people per sq. km of land area), 2011. Available at (Accessed 24 January 2012).
  • 22
    Achonu C, Rosella L, Gubbay JB et al. Seroprevalence of pandemic influenza H1N1 in Ontario from January 2009–May 2010. PLoS ONE 2011; 6:e26427.
  • 23
    Allwinn R, Geiler J, Berger A, Cinatl J, Doerr H. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol 2010; 199:117121.
  • 24
    Gilbert GL, Cretikos MA, Hueston L, Doukas G, O'Toole B, Dwyer DE. Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS ONE 2010; 5:e12562.
  • 25
    Ikonen N, Strengell M, Kinnunen L et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 2010; 15:pii: 19478.
  • 26
    Rizzo C, Rota MC, Bella A et al. Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 2010; 28:35583562.
  • 27
    Skowronski DM, Hottes TS, McElhaney JE et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 2011; 203:158167.
  • 28
    Tandale B, Pawar S, Gurav Y et al. Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, India. BMC Infect Dis 2010; 10:255.
  • 29
    Bandaranayake D, Huang QS, Bissielo A, Wood T. Seroprevalence of the 2009 influenza A (H1N1) pandemic in New Zealand, 2010. In: ESR, ed. Available at (Accessed 7 January 2013).
  • 30
    Bone A, Guthmann J-P, Assal A et al. Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France. PLoS ONE 2012; 7:e33056.
  • 31
    Dudareva S, Schweiger B, Thamm M et al. Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. PLoS ONE 2011; 6:e21340.
  • 32
    Iwatsuki-Horimoto K, Horimoto T, Tamura D et al. Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan. Clin Vaccine Immunol 2011; 18:860866.
  • 33
    Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375:11001108.
  • 34
    Waalen K, Kilander A, Dudman SG, Krogh GH, Aune T, Hungnes O. High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill 2010; 15:pii=19633. Available at
  • 35
    Xu C, Bai T, Iuliano AD et al. The seroprevalence of pandemic influenza H1N1 (2009) virus in China. PLoS ONE 2011; 6:e17919.
  • 36
    Chen M, Lee VJ, Lim WY et al. 2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 2010; 303:13831391.
  • 37
    Dellagi K, Rollot O, Temmam S et al. Pandemic influenza due to pH1N1/2009 virus: estimation of infection burden in Reunion Island through a prospective serosurvey, Austral Winter 2009. PLoS ONE 2011; 6:e25738.
  • 38
    McVernon J, Laurie K, Nolan T et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October–December 2009. Euro Surveill 2010; 15:pii=19678. Available at
  • 39
    Reed C, Katz JM, Hancock K, Balish A, Fry AM, for the H1N1 Serosurvey Working Group. Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic. PLoS One. 2012; 7:e48187.
  • 40
    Soh SE, Cook AR, Chen MIC et al. Teacher led school-based surveillance can allow accurate tracking of emerging infectious diseases – evidence from serial cross-sectional surveys of febrile respiratory illness during the H1N1 2009 influenza pandemic in Singapore. BMC Infect Dis 2012; 12:336.
  • 41
    Hardelid P, Andrews N, Hoschler K et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A H1N1 2009. Health Technol Assess 2010; 14:115192.
  • 42
    Horby P, Mai LQ, Fox A et al. The epidemiology of interpandemic and pandemic influenza in Vietnam, 2007–2010: the Ha Nam Household Cohort Study I. Am J Epidemiol 2012; 175:10621074.
  • 43
    Wu JT, Ma ES, Lee CK et al. A serial cross-sectional serologic survey of 2009 Pandemic (H1N1) in Hong Kong: implications for future pandemic influenza surveillance. Influenza Other Respi Viruses 2011; 5(Suppl. 1):190194.
  • 44
    Cox C, Goodin K, Fisher E et al. Prevalence of 2009 pandemic influenza A (H1N1) virus antibodies, Tampa Bay Florida – November–December, 2009. PLoS ONE 2011; 6:e29301.
  • 45
    Lapidus N, de Lamballerie X, Salez N et al. Integrative study of pandemic A/H1N1 influenza infections: design and methods of the CoPanFlu-France cohort. BMC Public Health 2012; 12:417.
  • 46
    Moghadami M, Moattari A, Tabatabaee HR et al. High titers of hemagglutination inhibition antibodies against 2009 H1N1 influenza virus in Southern Iran. Iran J Immunol 2010; 7:3948.
  • 47
    Skowronski DM, Hottes TS, Janjua NZ et al. Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. CMAJ 2010; 182:18511856.
  • 48
    Steens A, Waaijenborg S, Teunis PFM et al. Age-dependent patterns of infection and severity explaining the low impact of 2009 influenza A (H1N1): evidence from serial serologic surveys in the Netherlands. Am J Epidemiol 2011; 174:13071315, Epub 2011 Oct 24.
  • 49
    Zimmer SM, Crevar CJ, Carter DM et al. Seroprevalence following the second wave of pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS ONE 2010; 5:e11601.
  • 50
    Bandaranayake D, Huang QS, Bissielo A, et al. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS ONE 2010; 5:e13211.
  • 51
    Maltezou HC, Katerelos P, Mavrouli M et al. Seroepidemiological study of pandemic influenza H1N1 following the 2009–2010 wave in Greece. Vaccine 2011; 29:66646669.
  • 52
    Chi C-Y, Liu C-C, Lin C-C et al. Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population. Clin Vaccine Immunol 2010; 17:19581962.
  • 53
    Sigmundsdottir G, Gudnason T, Ólafsson Ö et al. Surveillance of influenza in Iceland during the 2009 pandemic. Euro Surveill 2010; 15:pii: 19742.
  • 54
    Elizondo-Montemayor L, Alvarez MM, Hernández-Torre M et al. Seroprevalence of antibodies to influenza A/H1N1/2009 among transmission risk groups after the second wave in Mexico, by a virus-free ELISA method. Int J Infect Dis 2011; 15:e781e786.
  • 55
    Kode SS, Pawar SD, Tandale BV, Parkhi SS, Barde TD, Mishra AC. Low level of cross-reactive antibodies to pandemic influenza (H1N1) 2009 virus in humans in pre-pandemic period in Maharashtra, India. Indian J Virol 2012; 23:3638.
  • 56
    Burmaa A, Tsatsral S, Odagiri T, Suzuki A, Oshitani H, Nymadawa P. Seroconversion rates of Pandemic Influenza A (H1N1) 2009 by a community-based cohort study in Selenghe Province, Mongolia. Influenza Other Respi Viruses 2012; doi: 10.1111/j.1750-2659.2012.00334.x.
  • 57
    Riley S, Kwok KO, Wu KM et al. Epidemiological characteristics of 2009 (H1N1) pandemic influenza based on paired sera from a longitudinal community cohort study. PLoS Med 2011; 8:e1000442.
  • 58
    Cowling BJ, Chan KH, Fang VJ et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010; 362:21752184.
  • 59
    Papenburg J, Baz M, Hamelin M-E et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis 2010; 51:10331041.
  • 60
    Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:19451952.
  • 61
    Verma N, Dimitrova M, Carter DM et al. Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children. J Virol 2012; 86:55155522. Epub 2012 Feb 29.
  • 62
    Stephenson I, Heath A, Major D et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009; 15:12521259.
  • 63
    Broberg E, Nicoll A, Amato-Gauci A. Seroprevalence to influenza A(H1N1) 2009 virus where are we? Clin Vaccine Immunol 2011; 18:12051212.
  • 64
    Chen MI, Barr IG, Koh GCH et al. Serological response in RT-PCR confirmed H1N1-2009 influenza A by hemagglutination inhibition and virus neutralization assays: an observational study. PLoS ONE 2010; 5:e12474.
  • 65
    Veguilla V, Hancock K, Schiffer J et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011; 49:22102215. Epub 2011 Apr 6. 2011.
  • 66
    Esposito S, Daleno C, Tagliabue C et al. Antibody response of healthy children to pandemic A/H1N1/2009 influenza virus. Virol J 2011; 8:563.
  • 67
    Delangue J, Salez N, Ninove L et al. Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population. Clin Microbiol Infect 2012; 18:177183.
  • 68
    Van Kerkhove MD, Mounts AW. 2009 Versus 2010 comparison of influenza activity in southern hemisphere temperate countries. Influenza Other Respi Viruses 2011; 5:375379.
  • 69
    Van Kerkhove MD, Mounts AW, Mall S et al. Epidemiologic and virologic assessment of the 2009 influenza A (H1N1) pandemic on selected temperate countries in the southern hemisphere: Argentina, Australia, Chile, New Zealand and South Africa. Influenza Other Respi Viruses 2011; 5:e487e498.
  • 70
    Koita OA, Sangare L, Poudiougou B et al. A seroepidemiological study of pandemic A/H1N1(2009) influenza in a rural population of Mali. Clin Microbiol Infect 2012; 18:976981.